Anavex Life Sciences Corp. (AVXL)
| Market Cap | 312.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.95M |
| Shares Out | 92.67M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 616,658 |
| Open | 3.230 |
| Previous Close | 3.290 |
| Day's Range | 3.230 - 3.385 |
| 52-Week Range | 2.610 - 13.990 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+552.82%) |
| Earnings Date | May 8, 2026 |
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 552.82% from the latest price.
News
Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The session highlighted strong phase IIb/III results for blarcamesine in Alzheimer's, with significant cognitive and biomarker benefits, a robust safety profile, and a focus on pivotal studies for regulatory approval. Expansion into Parkinson's and rare diseases is supported by mechanistic rationale and financial stability.
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Provides Comprehensive Regulatory Update
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group af...
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease
Findings underpin potential of Anavex' lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration Findings underpin potential of Anavex' lead candi...
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Park...
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Transcript: TD Cowen 46th Annual Health Care Conference
Presentations highlighted strong phase IIb/III results for blarcamesine in Alzheimer's, with significant cognitive and quality-of-life benefits, robust safety, and a focus on oral, patient-friendly solutions. The pipeline spans multiple CNS indications, supported by solid financials and IP.
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Earnings Call Transcript: Q1 2026
Cash position remains strong with over $131 million and no debt, supporting a multi-year runway. Regulatory engagement for blarcamesine continues in both the US and Europe, with new clinical trials and scientific publications planned. ACCESS-AD participation and reduced expenses highlight operational progress.
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 am Eastern Time
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET
Anavex Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation highlighted a precision medicine approach targeting upstream CNS disease mechanisms, with blarcamesine showing strong efficacy and safety in Alzheimer's trials. The oral therapy offers significant patient and caregiver benefits, robust financials, and a broad pipeline addressing major unmet needs.
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new...
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Dec. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Scien...
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Earnings Call Transcript: Q4 2025
Blarcamesine showed strong efficacy in early Alzheimer's, with significant slowing of cognitive decline and robust biomarker support, while ANAVEX3-71 advanced in schizophrenia. Cash runway exceeds three years, and a CHMP re-examination is planned following an expected negative opinion.
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcast t oday at 8:30 a.m. Eastern Time